chronic thromboembolic pulmonary hypertension

Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy

chronic thromboembolic pulmonary hypertension

Abbreviation: CTEPH
Pulmonary HTN that results from the migration of blood clots (usually from the lower extremities) into the lungs. Elevated BP in the lungs gradually overloads the right ventricle and causes right-sided heart failure.


Symptoms usually include shortness of breath, esp. during exercise.


The disease, when identified, may be treated with surgical removal of blood clots.

See also: hypertension
Medical Dictionary, © 2009 Farlex and Partners
References in periodicals archive ?
Iloprost for chronic thromboembolic pulmonary hypertension. Arch Bronconeumol 2004;40:326-8.
Fedullo, "Chronic thromboembolic pulmonary hypertension," Clinics in Chest Medicine, vol.
Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007; 74:287-293.
High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thromb Haemost 2003; 90: 372-6.
Chronic thromboembolic pulmonary hypertension (CTEPH) is a clinical syndrome characterized by obstruction of the pulmonary arteries with organized pulmonary thromboembolic and subsequent elevated blood pressure in the arteries.[sup][1] Although pulmonary endarterectomy (PEA) has been considered the treatment of choice and potential cure for CTEPH,[sup][2] approximately 20–40% of CTEPH patients are considered inoperable due to the predominant distal pulmonary arteriopathy or severe co-morbidities,[sup][3],[4] contributing to most deaths related to this disease.
The product is intended for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Plasma monocyte chemoattractant protein-1 and pulmoner vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2001; 164: 319-24.
Riociguat (BAY 63-2521) is an oral agent being investigated in Phase III clinical trials as a potentially new approach to treating in chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), two life-threatening types of PH.

Full browser ?